详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection.

11| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China. [2]Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China. [3]Department of Obstetrics and Gynecology, Shenzhen University General Hospital, Shenzhen, China. [4]Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, China. [5]Shenzhen Key Laboratory, Shenzhen University General Hospital, Shenzhen, China. [6]Department of Internal Medicine of Traditional Chinese Medicine, The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.

出处：

DOI：

ISSN：

关键词： puerarin COVID-19 COAD comorbidity network pharmacology bioinformatics

摘要：

Patients with colonic adenocarcinoma (COAD) are at relatively high risk of SARS-CoV-2 infection. However, there is a lack of medical strategies to treat COVID-19/COAD comorbidity. Puerarin, a natural product, is a known antiviral, antitumor, and immunomodulatory effect. Therefore, we hypothesised that puerarin could be used to treat COVID-19/COAD patients. Based on network pharmacology and bioinformatics analysis, the potential targets and pharmacological mechanisms of puerarin in COVID-19/COAD were identified. By intersecting therapeutic target genes for puerarin, COVID-19-related genes and COAD-related genes, 42 target genes of puerarin that could potentially treat COVID-19/COAD comorbidity were obtained. By using the 42 potential target genes to construct the protein-protein interaction (PPI) network, we obtained five core target genes, namely RELA, BCL2, JUN, FOS, and MAPK1. The results of bioinformatics analysis revealed that puerarin could be able to treat COVID-19/COAD comorbidity through apoptosis, antiviral, antioxidant, NF-κB signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and HIF-1 signaling pathway etc. This study found that puerarin has the potential to treat COVID-19/COAD patients and that the therapeutic target genes obtained in the study may provide clues for the treatment of COVID19/COAD comorbidity.Copyright © 2022 Liang, Li, Yao, Meng, Wu, Wang and Xue.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区

医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2020]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 4.4 最新[2023版] 5 最新五年平均 5.811 出版当年[2020版] 6.006 出版当年五年平均 4.225 出版前一年[2019版] 5.988 出版后一年[2021版]

第一作者：

第一作者机构： [1]Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China. [2]Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.

共同第一作者：

通讯作者：

通讯机构： [1]Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China. [2]Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China. [3]Department of Obstetrics and Gynecology, Shenzhen University General Hospital, Shenzhen, China. [4]Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, China. [5]Shenzhen Key Laboratory, Shenzhen University General Hospital, Shenzhen, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection.

文献详情

相关文献